Advocacy intelligence hub — real-time data for patient organizations
University of Pittsburgh — NA
Harmony Biosciences Management, Inc. — PHASE3
Mahidol University
Centre Hospitalier Universitaire de Nīmes
Nyree Penn — PHASE1
Stanford University — PHASE4
Centessa Pharmaceuticals (UK) Limited — PHASE2
University of Sydney — NA
Alkermes, Inc. — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs2
WAKIX
Harmony Biosciences Management, Inc.
Provigil
Cephalon, Inc.
Provigil
(Modafinil)Orphan drugCephalon, Inc.
Sympathomimetic-like Agent [EPC]
12.1 Mechanism of Action The mechanism(s) through which modafinil promotes wakefulness is unknown. Modafinil has wake-promoting actions similar to sym...
Lumryz
(sodium oxybate)Orphan drugstandardFlamel Ireland Limited dba Avadel Ireland
Omeprazole
(OMEPRAZOLE)Orphan drugstandardPD-Rx Pharmaceuticals, Inc.
Proton Pump Inhibitor [EPC]
12.1 Mechanism of Action Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretio...
Xywav
(calcium, magnesium, potassium, and sodium oxybates)Orphan drugstandardJazz Pharmaceuticals Ireland Limited
12.1 Mechanism of Action XYWAV is a CNS depressant. The exact mechanism of action of XYWAV in the treatment of narcolepsy and idiopathic hypersomnia i...
FDA Approves CABERGOLINE
CABERGOLINE (CABERGOLINE) received FDA approval.
Sleep time and SOREMPs features support idiopathic hypersomnia and narcolepsy type 2 as a single disease entity.
Idiopathic hypersomnia (IH) and narcolepsy type 2 (NT2) are rare hypersomnolence disorders with unknown pathophysiology. Recent evidence suggests they may belong to the same spectrum. This study compa...
Perspectives on idiopathic hypersomnia: diagnostic challenges, unknown pathophysiological, and emerging therapeutic strategies.
Idiopathic hypersomnia is a rare chronic neurological condition that may be characterized by excessive daytime sleepiness, and/or prolonged nocturnal sleep, and also sleep inertia, yet its underlying ...
Age at Onset and Delays in Diagnosis of Central Disorders of Hypersomnolence Over the Past 30 Years.
Patients with narcolepsy type 1 (NT1), type 2 (NT2), idiopathic hypersomnia (IH) usually suffer from symptoms for years, even decades, before being diagnosed. We aimed to assess age at onset, age at d...
Dynamic Functional Network Connectivity Patterns Distinguish Neurobiological Substrates of Narcolepsy Type 1 and Idiopathic Hypersomnia: Potential Biomarkers From Resting-State fMRI.
This study aimed to explore dynamic functional network connectivity (dFNC) differences between narcolepsy type 1 (NT1), idiopathic hypersomnia (IH), and healthy controls (HCs), and evaluate the potent...
Correction to: Clinical and polysomnographic changes in idiopathic hypersomnia ten years after the diagnosis.
Correction to: Clinical and polysomnographic changes in idiopathic hypersomnia ten years after the diagnosis.
Lynn Marie Trotti, MD
Emory University
Lynn Marie Trotti, MD, MSc
Emory University
Yves DAUVILLIERS
University Hospital, Montpellier
Yves DAUVILLIERS, MD PhD
University Hospital, Montpellier
Elisa EVANGELISTA
CHU de Nimes
📍 SACRAMENTO, CA
Laure PETER-DEREX, Professor
Hospices Civils de Lyon